Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Bajaj Auto Limited - Shareholders meeting

2018-07-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BAJAJ-AUTO 532977

0
Bajaj Auto Q1 profit up 24.5%

2018-07-21 freepressjournal.in
New Delhi : Bajaj Auto on Friday reported 24.5 per cent increase in consolidated net profit at Rs 1,041.78 crore for the first quarter ended June 30, 2018 riding on robust sales.
BAJAJ-AUTO 532977

0
Bajaj Auto Q1 profit rises 20.71%, misses estimates

2018-07-20 livemint
Mumbai: India’s second-largest motorcycle maker Bajaj Auto Ltd on Friday reported a 20.71% jump in June quarter (Q1) net profit, compared to the corresponding quarter of the previous year on the back of higher motorcycle and three-wheeler sales in domestic and overseas markets.
BAJAJ-AUTO 532977

0
Bajaj Auto skids as Q1 profits miss street expectations

2018-07-20 thehindubusinessline
Thanks to improving demand for bikes as well as better prospects in the export markets, Bajaj Auto posted double-digit growth in revenues and profits in the quarter ended June 2018. However, the stock was beaten down by 9 per cent on Friday after the results announcement, due to lower-than-expected profit growth as well as disappointment on the operating margin front.
BAJAJ-AUTO 532977

0
Bajaj Auto Limited - Shareholders meeting

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BAJAJ-AUTO 532977

0
Bajaj Auto shares skid over 9%

2018-07-20 thehindubusinessline
Shares of Bajaj Auto today plunged over 9 per cent, wiping out Rs 7,862 crore from its market valuation, after the company’s first quarter earnings came below market expectations.
BAJAJ-AUTO 532977

0
Bajaj Auto restructures portfolio of four senior personnel

2018-07-20 moneycontrol
Bajaj Auto, country’s third largest two-wheeler maker has restructured portfolios of four top executives that included the creation of a new position to accelerate growth.
BAJAJ-AUTO 532977

0
Bajaj Auto reports 20.7% rise in Q1 standalone net profit to Rs 1,115 crore, misses estimates

2018-07-20 moneycontrol
India's third largest two-wheeler maker Bajaj Auto on Friday missed analysts' expectations by reporting a 20.7 percent year-on-year rise in its standalone net profit for the quarter ended June.
BAJAJ-AUTO 532977

0
Bajaj Auto Limited - Outcome of Board Meeting

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BAJAJ-AUTO 532977

0
Bajaj Auto Limited - Financial Result Updates

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BAJAJ-AUTO 532977

0
Wipro, Bajaj Auto, MCX, HDFC Life, Ceat results

2018-07-19 thehindubusinessline
Around two dozen companies including Atul, Bajaj Auto, Bajaj Holdings, Bata India, Capital Trust, Ceat, Chowgule Steamships, Diligent Media, HDFC Standard Life Insurance, Havells India, Infomedia Press, Kansai Nerolac Paints, L&T Finance Holdings, MCX, Nelco, Onward Technologies, Radhe Developers, Ramgopal Polytex, Sanwaria Consumer, Wipro and Zee Media Corporation will declare their quarterly numbers for the period ended June 2018 on Friday.
BAJAJ-AUTO RADHEDE CHOWGULSTM 517354 501833 HVLQY ONWARDTEC KNZAY 517536 532977 BATAINDIA 531273 KANSAINER 511505 HAVELLS INFOMEDIA CAPITALT 509069 500043 500165

1
Sensex slips from record on profit-booking

2018-07-19 freepressjournal.in
Mumbai: The BSE Sensex retreated from record high to end flat at 36,541.63 today in volatile trade as investors booked profit in recent gainers despite firm global cues.
BAJAJ-AUTO 500325 RELIANCE 532977 BHRQY 533278 532215 500470 AXISBANK RIGD HDFCBANK HEROMOTOCO BHARTIARTL CLNDY RLNIY YESBANK AXB IBN 532648 YYBKY AXBKY 500182 532454 AXBA ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 HRTQY COALINDIA

0
Bajaj Auto Q1 Preview: Expect double digit growth in net profit

2018-07-19 moneycontrol
Bajaj Auto, the country's third largest two-wheeler maker, is likely to post a double digit rise in net profit for the quarter ended June on the back of a surge in exports.
BAJAJ-AUTO 500182 HEROMOTOCO 532977 HRTQY

0
BMW launches bikes G310 R at Rs 2.99 lakh, G310 GS at Rs 3.99 lakh

2018-07-18 moneycontrol
German motorcycle heavyweight BMW Motorrad has launched the much- awaited G310 R and G310 GS in India priced at Rs 2.99 lakh and Rs 3.49 lakh (ex-showroom), respectively.
BAJAJ-AUTO 532343 TVSMOTOR 532977

0
Bajaj Auto Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BAJAJ-AUTO 532977

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...